Work

A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis

Year: 2017

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: British Journal of Haematology

DOI: 10.1111/bjh.14501

Authors: Srdan Verstovsek, Michael R. Savona, Ruben A. Mesa, Hua Dong, Julia D. Maltzman, Shringi Sharma, Jeffrey Silverman, Stephen T. Oh, Jason Gotlib

Institutions: The University of Texas MD Anderson Cancer Center, Vanderbilt University, Mayo Clinic in Arizona, Gilead Sciences (United States), Washington University in St. Louis, Stanford Medicine, Stanford Cancer Institute, Stanford University

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Gilead Sciences, Karyopharm Therapeutics, Incyte, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2590741349

FWCI: 3.143

Cites: 26

Cited by: 49

Related to: 10